Aklief (trifarotene) is filed as Topical Retinoid. The sections below restate public label fields stored for this profile.
1 INDICATIONS AND USAGE AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ( 1 )
12.1 Mechanism of Action Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cell differentiation and mediation of inflammation. The exact process by which trifarotene ameliorates acne is unknown.
5 WARNINGS AND PRECAUTIONS Skin irritation: Erythema, scaling, dryness, and stinging/burning may be experienced with use of AKLIEF Cream. Use a moisturizer from the initiation of treatment, and, if appropriate, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. ( 5.1 ) Ultraviolet Light and Environmental Exposure: Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided. ( 5.2 ) 5.1 Skin Irritation Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Maximum severity of these reactions typically occurred within the first 4 weeks of treatment, and severity decreased with continued use of the medication. Depending upon the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of application of AKLIEF Cream, or suspend use temporarily. If severe reactions persist the treatment may be discontinued. Avoid application of AKLIEF Cream to cuts, abrasions, or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. 5.2 Ultraviolet Light and Environmental Exposure Minimize unprotected exposure to ultraviolet rays (including sunlight and sunlamps) during treatment with AKLIEF Cream. Warn patients who normally experience high levels of sun exposure and those with inherent sensitivity to sun to exercise caution. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided.
4 CONTRAINDICATIONS None None ( 4 )
Tire trial were application site pruritus (4.6%); Application site irritation (4.2%); And sunburn (5.5%)
2 DOSAGE AND ADMINISTRATION Apply a thin layer of AKLIEF Cream to the affected areas once daily, in the evening, on clean and dry skin. One pump actuation should be enough to cover the face (i.e., forehead, cheeks, nose, and chin). Two actuations of the pump should be enough to cover the upper trunk (i.e., reachable upper back, shoulders and chest). One additional pump actuation may be used for middle and lower back if acne is present. The use of a moisturizer is recommended as frequently as needed from the initiation of treatment. Avoid contact with the eyes, lips, paranasal creases, mucous membranes. AKLIEF Cream is for topical use only. Not for oral, ophthalmic, or intravaginal use. For topical use only. Not for oral, ophthalmic or intravaginal use. Apply a thin layer of AKLIEF Cream to the affected areas of the face and/or trunk once a day, in the evening, on clean and dry skin. Avoid contact with the eyes, lips, paranasal creases, and mucous membranes. ( 2 )
7 DRUG INTERACTIONS Topical application of AKLIEF Cream is not expected to affect the circulating concentrations of oral hormonal contraceptives containing ethinyl estradiol and levonorgestrel.
According to its FDA label, Aklief (trifarotene) is approved for: 1 INDICATIONS AND USAGE AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ( 1 ) For medical advice, please talk to your prescriber or pharmacist.
Aklief (trifarotene) belongs to the Topical Retinoid class of medications.
The FDA label lists Aklief (trifarotene) as: 3 DOSAGE FORMS AND STRENGTHS Cream: 0.005%. Each gram of AKLIEF Cream contains 50 mcg of trifarotene in a white cream. Cream: 0.005% trifarotene. ( 3 ); topical route. Available strengths and packaging vary by manufacturer.
Our ingest of the FDA label for Aklief (trifarotene) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
Public CMS NADAC pricing for Aklief (trifarotene) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.
The FDA Enforcement Report does not show an active/ongoing recall for Aklief (trifarotene) in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA record lists the approval date for Aklief (trifarotene) as 2019-10-04.
The FDA label lists Galderma Laboratories, L.P. as a labeler/manufacturer of Aklief (trifarotene). Multiple firms may market generics of the same molecule.
The FDA label states: "AKLIEF Cream, 0.005% is provided as a white cream supplied in the following packaging configurations with corresponding NDC numbers: 45-gram pump NDC 0299-5935-45 Storage and Handling - Store at 20˚ to 25˚C (68˚ to 77˚F)…" Follow the packaging insert for the authoritative guidance.
Loading full data from Know Your Drugs Institute…